ASCO26 Podcast: an analyst rundown of the best readouts and key trends
In this episode, two oncology analysts share their insights from the ASCO show floor, while talking through the readouts that excited them most.
Therapy Area
ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess
ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC
ASCO26: In vivo oncology approaches continue to show promise
Emerging therapies for CNS tumours: key clinical trial updates to watch at ASCO 2026
ATS 2026: Insmed shines in bronchiectasis with spotlight on Brinsupri
ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer
ASCO26: Platinum-resistant ADC leader Elahere stumbles in platinum-sensitive disease
